RxDoctor Payments Data

Norman Gray, MD

Cardiovascular Disease · Lakewood, CONPI 1437295698

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,596 of the $14,345 with a category attached, or 87.8%. 44 manufacturers reported payments, led by Boston Scientific at 27.7% of the total. Reporting peaked in 2024 at $3,258 and has fallen 57.0% since, to $1,401 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,345in general payments, 2019–2025

Across 547 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Abiomed$944
  • Pfizer$914
  • Novartis$784
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$270%
  • Travel & lodging$1,47110%
  • Food & beverage$12,59688%
  • Education$260%
  • Other$2242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,345 in reported general payments places this provider in the 90th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$222,896
Medicare patients
776
Services billed
2,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban517$594,625
VyndamaxTafamidis17$359,888
XareltoRivaroxaban229$265,502
Repatha SureclickEvolocumab173$128,024
EntrestoSacubitril/Valsartan68$80,114
JardianceEmpagliflozin55$64,372
MultaqDronedarone Hcl26$48,485
FarxigaDapagliflozin Propanediol23$29,410
BrilintaTicagrelor12$6,317
Atorvastatin Calcium475$3,949
Metoprolol Succinate354$3,544
Rosuvastatin Calcium244$2,362
ClopidogrelClopidogrel Bisulfate228$2,197
Losartan Potassium227$2,068
Carvedilol210$2,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$914$954,513534 claims
Johnson & JohnsonXarelto$1,160$265,502229 claims
NovartisEntresto$784$80,11468 claims
Boehringer IngelheimJardiance$739$64,37255 claims
Sanofi-aventis U.S. LLCMultaq$304$48,48526 claims
AstraZenecaFarxiga, Brilinta$564$35,72735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →